SCHEMBL2942290

SCHEMBL2942290

CCCCCc1ccccc1NC(=S)NC(=O)c1cc2cccnc2o1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
ALDH1A1 P00352 8/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
P2RX4 Q99571 1/20 0.40
P2RX7 Q99572 1/20 0.40
HPGD P15428 1/20 0.40
MIF P14174 1/20 0.40
POLB P06746 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13175642 0.85 MAPT (0.52) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL2911452 0.82 ALDH1A1 (0.52) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL2918340 0.82 ALDH1A1 (0.52) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL2942288 0.80 ALDH1A1 (0.45) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL2942862 0.80 CYP1A2 (0.40) NPC1RAB9AALDH1A1MAPTNPSR1
SCHEMBL2943798 0.79 ALDH1A1 (0.50) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL14096076 0.77 NPC1 (0.56) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL2943340 0.74 MAPT (0.55) NPC1RAB9AALDH1A1MAPTL3MBTL1
SCHEMBL11876861 0.70 LMNA (0.54) ALDH1A1MAPTHTTKMT2ASMN1; SMN2
SCHEMBL13956740 0.70 MAPT (0.73) NPC1RAB9AALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP claimed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US claimed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US claimed
EP-1709047-B1 AZABENZOFURAN SUBSTITUTED THIOUREAS AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS INC (US) 2010-09-01 EP disclosed
US-7439374-B2 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228013-A1 Azabenzofuran substituted thioureas; inhibitors of viral replication NAT1, PIGS, ADORA1 NPC1 491/4885RAB9A 1975/4885ALDH1A1 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.